Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | ATP4A | P20648 | 2/20 | 0.34 |
| ▸ | ATP4B | P51164 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744048 | 0.88 | ELANE (0.37) | ELANEATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL6672735 | 0.88 | ELANE (0.37) | ELANEATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5037175 | 0.83 | ELANE (0.35) | ELANEATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL6529295 | 0.83 | ELANE (0.35) | ELANEATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL7107773 | 0.83 | ELANE (0.35) | ELANEATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5744537 | 0.82 | ELANE (0.39) | ELANE | |
| SCHEMBL5746631 | 0.77 | ELANE (0.34) | ELANEATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4972816 | 0.76 | ELANE (0.32) | ELANE | |
| SCHEMBL4972810 | 0.76 | ELANE (0.32) | ELANE | |
| SCHEMBL1815255 | 0.74 | RET (0.36) | ATP4AATP4BCYP3A4CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314935-B2 | Tricyclic n-acyl compounds | ALTANA PHARMA AG (DE) | 2008-01-01 | — | — | US | disclosed |
| US-20050148618-A1 | Tricyclic n-acyl compounds | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | US | disclosed |
| EP-1476445-A1 | TRICYCLIC N-ACYL COMPOUNDS | ALTANA Pharma AG (DE) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068774-A1 | TRICYCLIC N-ACYL COMPOUNDS | ALTANA PHARMA AG (DE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148618-A1 | Tricyclic n-acyl compounds | NAT1, AADAC, CYP1B1 | ELANE 671/4885ATP4A 2068/4885ATP4B 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.